WO2005053708A1 - ロテプレドノールエタボネート水性懸濁液剤 - Google Patents
ロテプレドノールエタボネート水性懸濁液剤Info
- Publication number
- WO2005053708A1 WO2005053708A1 PCT/JP2004/017762 JP2004017762W WO2005053708A1 WO 2005053708 A1 WO2005053708 A1 WO 2005053708A1 JP 2004017762 W JP2004017762 W JP 2004017762W WO 2005053708 A1 WO2005053708 A1 WO 2005053708A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- aqueous suspension
- loteprednol etabonate
- container
- acid
- paraoxybenzoate
- Prior art date
Links
- DMKSVUSAATWOCU-HROMYWEYSA-N loteprednol etabonate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)OCCl)(OC(=O)OCC)[C@@]1(C)C[C@@H]2O DMKSVUSAATWOCU-HROMYWEYSA-N 0.000 title claims abstract description 24
- 229960003744 loteprednol etabonate Drugs 0.000 title claims abstract description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title abstract description 24
- 239000000203 mixture Substances 0.000 title abstract description 21
- 238000009472 formulation Methods 0.000 title abstract description 17
- 239000000725 suspension Substances 0.000 title abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims abstract description 13
- 235000010199 sorbic acid Nutrition 0.000 claims abstract description 13
- 239000004334 sorbic acid Substances 0.000 claims abstract description 13
- 229940075582 sorbic acid Drugs 0.000 claims abstract description 13
- 238000000034 method Methods 0.000 claims abstract description 7
- 239000002736 nonionic surfactant Substances 0.000 claims abstract description 7
- 239000007900 aqueous suspension Substances 0.000 claims description 65
- 239000003221 ear drop Substances 0.000 claims description 7
- 239000007923 nasal drop Substances 0.000 claims description 7
- 229950009769 etabonate Drugs 0.000 claims description 5
- 239000003889 eye drop Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 abstract description 14
- 239000002253 acid Substances 0.000 abstract description 8
- 230000015572 biosynthetic process Effects 0.000 abstract description 7
- 150000002148 esters Chemical class 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 20
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 18
- 235000002639 sodium chloride Nutrition 0.000 description 16
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 15
- 229940037001 sodium edetate Drugs 0.000 description 15
- SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 14
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 12
- 229960002684 aminocaproic acid Drugs 0.000 description 11
- 239000004302 potassium sorbate Substances 0.000 description 11
- 235000010241 potassium sorbate Nutrition 0.000 description 11
- 229940069338 potassium sorbate Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 9
- 235000011187 glycerol Nutrition 0.000 description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 9
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 9
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 8
- 239000002997 ophthalmic solution Substances 0.000 description 8
- 229940054534 ophthalmic solution Drugs 0.000 description 8
- 239000013049 sediment Substances 0.000 description 8
- MDYZKJNTKZIUSK-UHFFFAOYSA-N tyloxapol Chemical compound O=C.C1CO1.CC(C)(C)CC(C)(C)C1=CC=C(O)C=C1 MDYZKJNTKZIUSK-UHFFFAOYSA-N 0.000 description 8
- 229960004224 tyloxapol Drugs 0.000 description 8
- 229920001664 tyloxapol Polymers 0.000 description 8
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- -1 aliphatic amino acids Chemical class 0.000 description 6
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 6
- 239000004327 boric acid Substances 0.000 description 6
- 235000010338 boric acid Nutrition 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 229940047652 ear drops Drugs 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 229960004926 chlorobutanol Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229940100662 nasal drops Drugs 0.000 description 4
- 238000004062 sedimentation Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 229960000686 benzalkonium chloride Drugs 0.000 description 3
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
- 229910021538 borax Inorganic materials 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000004328 sodium tetraborate Substances 0.000 description 3
- 235000010339 sodium tetraborate Nutrition 0.000 description 3
- 229920003169 water-soluble polymer Polymers 0.000 description 3
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229940100654 ophthalmic suspension Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 229940075554 sorbate Drugs 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- YUTUUOJFXIMELV-UHFFFAOYSA-N 2-Hydroxy-2-(2-methoxy-2-oxoethyl)butanedioic acid Chemical compound COC(=O)CC(O)(C(O)=O)CC(O)=O YUTUUOJFXIMELV-UHFFFAOYSA-N 0.000 description 1
- DUAYDERMVQWIJD-UHFFFAOYSA-N 2-n,2-n,6-trimethyl-1,3,5-triazine-2,4-diamine Chemical compound CN(C)C1=NC(C)=NC(N)=N1 DUAYDERMVQWIJD-UHFFFAOYSA-N 0.000 description 1
- KFYRPLNVJVHZGT-UHFFFAOYSA-N Amitriptyline hydrochloride Chemical compound Cl.C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KFYRPLNVJVHZGT-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HCVBQXINVUFVCE-UHFFFAOYSA-N Citronensaeure-beta-methylester Natural products COC(=O)C(O)(CC(O)=O)CC(O)=O HCVBQXINVUFVCE-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 206010022941 Iridocyclitis Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- FQISKWAFAHGMGT-SGJOWKDISA-M Methylprednisolone sodium succinate Chemical compound [Na+].C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)COC(=O)CCC([O-])=O)CC[C@H]21 FQISKWAFAHGMGT-SGJOWKDISA-M 0.000 description 1
- 229920001007 Nylon 4 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010039705 Scleritis Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 239000004283 Sodium sorbate Substances 0.000 description 1
- 241000245665 Taraxacum Species 0.000 description 1
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005054 agglomeration Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229920006318 anionic polymer Polymers 0.000 description 1
- 201000004612 anterior uveitis Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- KYZHGEFMXZOSJN-UHFFFAOYSA-N benzoic acid isobutyl ester Natural products CC(C)COC(=O)C1=CC=CC=C1 KYZHGEFMXZOSJN-UHFFFAOYSA-N 0.000 description 1
- 208000010217 blepharitis Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229960002645 boric acid Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229920000831 ionic polymer Polymers 0.000 description 1
- 201000004614 iritis Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- BJHIKXHVCXFQLS-OTWZMJIISA-N keto-L-sorbose Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)C(=O)CO BJHIKXHVCXFQLS-OTWZMJIISA-N 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000011163 secondary particle Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229960004249 sodium acetate Drugs 0.000 description 1
- 229960002668 sodium chloride Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229960001790 sodium citrate Drugs 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- LROWVYNUWKVTCU-STWYSWDKSA-M sodium sorbate Chemical compound [Na+].C\C=C\C=C\C([O-])=O LROWVYNUWKVTCU-STWYSWDKSA-M 0.000 description 1
- 235000019250 sodium sorbate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000015096 spirit Nutrition 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 206010044325 trachoma Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Definitions
- the present invention relates to an aqueous suspension and an aqueous suspension comprising loteprednol etabonate, and at least one selected from the group consisting of sorbic acid or a salt thereof and paraoxybenzoate.
- the present invention relates to a method for improving the redispersibility of loteprednol etabonate contained in a liquid preparation.
- Loteprednol etabonate (hereinafter sometimes referred to as LE) is a steroid having an anti-inflammatory effect. Since LE is a crystalline substance that is hardly soluble in water, LE is in the form of a suspension when used as an aqueous solution.
- Aqueous suspensions are difficult to re-disperse due to agglomeration of drug particles during storage for a long period of time, adhesion or adsorption to the walls of containers, and formation of secondary particles (block formation) of settled particles. It will be difficult.
- an aqueous suspension having improved redispersibility contains a water-soluble polymer and a sparingly soluble drug in a concentration range from the concentration at which the surface tension of the liquid starts to decrease to the concentration at which the surface tension stops decreasing.
- Aqueous suspension (see Patent Document 1), an aqueous suspension type ophthalmic solution of a sparingly soluble drug which combines an ionic polymer and a metal ion and has a viscosity of less than 100 cP (see Patent Document 2), a sparingly soluble drug, Aqueous suspension containing polybulpyrrolidone and water-soluble anionic polymer (see Patent Document 3), D-mannitol, D-sorbitol, xylitol, propylene glycol and citrate as suspending agents, and the like
- An aqueous suspension of a sparingly soluble drug containing a suspending agent selected from the group consisting of the following mixtures (see Patent Document 4) and the like have been reported.
- aqueous suspension containing LE a composition containing LE, a nonionic polymer, a nonionic surfactant and a nonionic tonicity agent
- LE an aqueous suspension containing aliphatic amino acids having 2 to 7 carbon atoms
- Patent Document 7 an aqueous suspension for nasal drops containing LE and crystalline cellulose.
- Carmellose sodium see Patent Document 7). See).
- Patent Document 1 Japanese Patent Application Laid-Open No. H11-29463
- Patent Document 2 JP-A-8-295622
- Patent Document 3 WO 02/15878 pamphlet
- Patent Document 4 JP-A-10-36253
- Patent Document 5 US Pat. No. 5,540,930
- Patent Document 6 JP-A-10-316572
- Patent Document 7 JP-A-10-259132
- the present invention provides an aqueous suspension comprising LE, and at least one selected from the group consisting of sorbic acid or a salt thereof and paraoxybenzoate.
- the present invention further provides a method for improving the redispersibility of LE contained in an aqueous suspension.
- an aqueous suspension containing LE contains at least one selected from the group consisting of sorbic acid or a salt thereof and paraoxybenzoic acid ester. was found to prevent the sedimentation of LE particles from sticking to the container and the formation of blocks, and to improve redispersibility.Based on this finding, further research was conducted to complete the present invention. Reached.
- Aqueous suspension comprising loteprednol etabonate and at least one selected from the group consisting of sorbic acid or a salt thereof and paraoxybenzoic acid ester
- precipitated LE is mixed with an aqueous suspension containing LE and at least one selected from the group consisting of sorbic acid or a salt thereof, and paraoxybenzoate. It is possible to provide an aqueous LE-containing suspension in which adhesion of particles to a container and block formation are suppressed and redispersibility is improved.
- the lower limit concentration of the LE concentration in the aqueous suspension of the present invention is usually about 0.01 w / v%, preferably about 0.05 w / v%, more preferably about 0.05 w / v%, as long as it is a concentration that is therapeutically effective for inflammation. Is about 0.1 lw / v%, and the upper limit concentration is usually about 2. OwZv%, preferably about 1.5 w / v%, more preferably about 1. OwZv%.
- Sorbic acid or a salt thereof used in the present invention includes sorbic acid, potassium sorbate, sodium sorbate and the like. Preferred is potassium sorbate.
- the concentration of sorbic acid or a salt thereof in the aqueous suspension of the present invention is not particularly limited, but the lower limit is usually about 0.001 w / v%, preferably about 0.005 w / v%, and the upper limit is usually It is about 5. Ow / v%, preferably about 1. Ow / v%.
- paraoxybenzoic acid ester used in the present invention those which are esterified with a lower alkyl group are preferable, and methyl paraoxybenzoate, ethyl paraoxybenzoate, propyl paraoxybenzoate, and paraoxybenzoic acid are preferred. Isopropyl, parabutyl benzoate, and isobutyl benzoate.
- concentration of paraoxybenzoate in the aqueous suspension of the present invention is not particularly limited, but the lower limit is usually about 0.001 w / v%, preferably about 0.01 w / v%, and the upper limit is usually It is about 1. Ow / v%, preferably about 0.1 lw / v%.
- a nonionic surfactant is used.
- the nonionic surfactant to be used include tyloxapol, polysorbate 80, and polypropylene glycol / ethylene oxide block polymer. Preferred is tyloxapol.
- the concentration of the nonionic surfactant in the aqueous suspension of the present invention is not particularly limited, but the lower limit is usually about 0.01 wZv%, preferably about 0.05 w / v%, The upper limit is usually about 5.0 w / v%, preferably about 1.0 wZv%.
- the aqueous suspension of the present invention includes, for example, isotonicity agents (such as sodium chloride, potassium chloride, glycerin, mannitol, sonorebitone, propylene glycol, and boric acid), and a buffer (such as phosphoric acid).
- isotonicity agents such as sodium chloride, potassium chloride, glycerin, mannitol, sonorebitone, propylene glycol, and boric acid
- a buffer such as phosphoric acid
- Buffer acetate buffer, borate buffer, carbonate buffer, citrate buffer, Tris buffer, gnoletamic acid, ⁇ -aminocaproic acid, sodium acetate, boric acid, borax, etc., preservatives (chlorobutanol, Benzyl alcohol, sodium dehydroacetate, sodium edetate, benzanolecone chloride, salted benzene, boric acid, borax, etc., water-soluble polymers (hydroxyxenoresenorelose, hydroxypropinoresenorelose) , Hydroxypropinolemethinole cellulose, polyvinyl alcohol, polyvinylpyrrolidone, etc.), stabilizers Sodium hydrogen sulfite, sodium thiosulfate, sodium edetate, sodium citrate, sodium acetate, ascorbic acid, dibutylhydroxytoluene, boric acid, borax, etc., ⁇ modifier (hydrochloric acid, sodium hydroxide, phosphoric acid
- the amount of these additives may vary depending on the type and use of the additives to be added.
- the additives may be added at a concentration that can achieve the purpose of the additives.
- the buffer is about 0.01 to about 2.
- the water-soluble polymer is about 0.0001 and about 2.
- the stabilizer is about 0.001 to about 1.
- OwZv. Add about%.
- the pH adjuster is added as appropriate, and the pH is usually adjusted to about 4.0 to about 9.0, preferably to about 5.0 to about 8.0. Add about 0.001 to about 3. Ow / v% of preservative.
- the aqueous suspension of the present invention contains pharmaceutical ingredients other than LE, such as a therapeutic agent for glaucoma, a steroidal or non-steroidal anti-inflammatory agent, an antibacterial agent, and the like, as long as the object of the present invention is not adversely affected.
- a vasoconstrictor, an antiallergic agent, an antihistamine, an antiviral agent, and the like may be mixed and formulated.
- the aqueous suspension of the present invention Since the aqueous suspension of the present invention has excellent redispersibility, it can be used as a medicament (eg, an allergic agent, a prophylactic or therapeutic agent for inflammation), an animal drug, and the like for humans and non-human mammals (eg, , Rat, mouse, guinea pig, monkey, dog, dog, pig, etc.).
- the aqueous suspension of the present invention can be suitably used as eye drops, nasal drops, ear drops, injections, oral liquids, liniments, lotions, and the like. Ear drops are preferred.
- the aqueous suspension of the present invention may be used in various types of eyes such as conjunctivitis, blepharitis, keratitis, scleritis, LTDis, iridocyclitis, uveitis, postoperative inflammation, allergic conjunctivitis, trachoma, etc.
- ophthalmic solution containing 0.5 wZv% LE for adults against inflammation, it may be administered once or twice a day, 35 times a day.
- the aqueous suspension of the present invention can be produced by a method known per se, for example, a method described in Japanese Pharmacopoeia XIV, Liquid, Suspension or Eye Drops of the General Rules for Preparations.
- a method known per se for example, a method described in Japanese Pharmacopoeia XIV, Liquid, Suspension or Eye Drops of the General Rules for Preparations.
- PP polypropylene
- Mi fan ml 100 ml. 100 mL 100 mL pH 5.5 5.5 ⁇ . ⁇ 5.B
- Paraoxy-ammonium, methyl citrate 0.026 g Paraoxy-encapsulated pill 0,014 g Thyloxabo / 0.2 g 0.2 g 0.2 g ⁇ -Aminocaproic acid 0.2 g 0.2 g 0.2 g Concentrated glycerin 2.6 g 2.6 g Boric acid lB g
- potassium sorbate, tyloxapol, ⁇ -aminocaproic acid, sodium chloride, sodium edetate, and benzanolecone chloride were dissolved in about 80 mL of sterile purified water.
- Loteprednol etabonate was added, the mixture was uniformly suspended with a homogenizer, and ⁇ was adjusted to 5.5 by adding hydrochloric acid. The total amount was made up to 100 mL with sterile purified water to prepare an aqueous suspension ophthalmic solution containing loteprednol etabonate.
- methyl paraoxybenzoate, propyl paraoxybenzoate, tyloxapol, ⁇ -aminocaproic acid, concentrated glycerin and sodium edetate were added to about 80 mL of sterile purified water and dissolved.
- Loteprednol etabonate was added, the mixture was uniformly suspended with a homogenizer, and the pH was adjusted to 5.5 by adding hydrochloric acid. The total amount was made up to 100 mL with sterile purified water to prepare an aqueous ophthalmic suspension containing loteprednol etabonate.
- methyl paraoxybenzoate, propyl paraoxybenzoate, tyloxapol, chlorobutanol, ⁇ -aminocaproic acid, concentrated glycerin, polybutylpyrrolidone III-30 and sodium edetate were added to about 80 mL of sterile purified water and dissolved.
- methyl paraoxybenzoate, propyl paraoxybenzoate, tyloxapol, chlorobutanol, ⁇ -aminocaproic acid, concentrated dariserin and sodium edetate were added to about 80 mL of sterilized purified water and dissolved.
- the amount of loteprednol etabonate was caloried, suspended uniformly with a homogenizer, and the pH was adjusted to 5.5 by adding hydrochloric acid. The total amount was made up to 100 mL with sterile purified water to prepare an aqueous suspension ophthalmic solution containing toluene.
- potassium sorbate, tyloxapol, ⁇ -aminocaproic acid, boric acid, sodium edetate and benzalkonium chloride were added to about 80 mL of sterile purified water and dissolved.
- Loteprednol etabonate was mashed, suspended uniformly with a homogenizer, and adjusted to pH 5.5 with hydrochloric acid. The total amount was made up to 100 mL with sterile purified water to prepare an aqueous suspension nasal drop containing oral teprednol etabonate.
- methyl paraoxybenzoate, propyl paraoxybenzoate, tyloxapol, chlorobutanol, ⁇ -aminocaproic acid, concentrated glycerin, and sodium edetate were dissolved in about 80 mL of sterilized purified water.
- the amount of loteprednol etabonate was caloried, suspended uniformly with a homogenizer, and the pH was adjusted to 5.5 by adding hydrochloric acid. Sterilized purified water was added to make the total volume 100 mL, and loteprednol etabonate-containing aqueous suspension eardrops were prepared.
- sorbin is added to an aqueous suspension containing loteprednol etabonate.
- the rotor which has been improved in redispersibility by suppressing sedimentation of LE particles settled in a container and formation of blocks, and by improving redispersibility.
- An aqueous suspension containing prednol etabonate can be provided. Since the aqueous suspension of the present invention has good redispersibility, it can be used as excellent eye drops, nasal drops and ear drops.
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005515924A JP4820648B2 (ja) | 2003-12-02 | 2004-11-30 | ロテプレドノールエタボネート水性懸濁液剤 |
US10/581,244 US20080306039A1 (en) | 2003-12-02 | 2004-11-30 | Loteprednol Etabonate Aqueous Suspension |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003-403719 | 2003-12-02 | ||
JP2003403719 | 2003-12-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005053708A1 true WO2005053708A1 (ja) | 2005-06-16 |
Family
ID=34650084
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/017762 WO2005053708A1 (ja) | 2003-12-02 | 2004-11-30 | ロテプレドノールエタボネート水性懸濁液剤 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20080306039A1 (ja) |
JP (1) | JP4820648B2 (ja) |
WO (1) | WO2005053708A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011034192A1 (ja) * | 2009-09-17 | 2011-03-24 | 千寿製薬株式会社 | ラタノプロストを含有する水性点眼剤、並びにラタノプロストの樹脂への吸着の抑制方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10864219B2 (en) * | 2012-05-03 | 2020-12-15 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
CA2871745C (en) | 2012-05-03 | 2023-01-24 | Kala Pharmaceuticals, Inc. | Pharmaceutical nanoparticles showing improved mucosal transport |
US9827191B2 (en) * | 2012-05-03 | 2017-11-28 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
KR102140989B1 (ko) | 2012-05-03 | 2020-08-04 | 칼라 파마슈티컬스, 인크. | 개선된 점막 수송을 나타내는 제약 나노입자 |
US11596599B2 (en) * | 2012-05-03 | 2023-03-07 | The Johns Hopkins University | Compositions and methods for ophthalmic and/or other applications |
CN115737547A (zh) * | 2022-11-21 | 2023-03-07 | 山东诺明康药物研究院有限公司 | 一种氯替泼诺温度敏感型原位凝胶滴眼液及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08151332A (ja) * | 1994-09-28 | 1996-06-11 | Senju Pharmaceut Co Ltd | 点鼻用水性懸濁液 |
JPH10259132A (ja) * | 1997-01-16 | 1998-09-29 | Senju Pharmaceut Co Ltd | 点鼻用水性懸濁液 |
JPH10316572A (ja) * | 1997-03-14 | 1998-12-02 | Senju Pharmaceut Co Ltd | ロテプレドノール エタボネート水性懸濁液 |
JP2000007569A (ja) * | 1998-06-19 | 2000-01-11 | Senju Pharmaceut Co Ltd | 嗅覚障害治療剤 |
WO2002015878A1 (en) * | 2000-08-25 | 2002-02-28 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension preparations |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5540930A (en) * | 1993-10-25 | 1996-07-30 | Pharmos Corporation | Suspension of loteprednol etabonate for ear, eye, or nose treatment |
JP3402195B2 (ja) * | 1997-05-14 | 2003-04-28 | 千寿製薬株式会社 | 再分散性の良い水性懸濁液剤 |
-
2004
- 2004-11-30 WO PCT/JP2004/017762 patent/WO2005053708A1/ja not_active Application Discontinuation
- 2004-11-30 US US10/581,244 patent/US20080306039A1/en not_active Abandoned
- 2004-11-30 JP JP2005515924A patent/JP4820648B2/ja not_active Expired - Fee Related
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08151332A (ja) * | 1994-09-28 | 1996-06-11 | Senju Pharmaceut Co Ltd | 点鼻用水性懸濁液 |
JPH10259132A (ja) * | 1997-01-16 | 1998-09-29 | Senju Pharmaceut Co Ltd | 点鼻用水性懸濁液 |
JPH10316572A (ja) * | 1997-03-14 | 1998-12-02 | Senju Pharmaceut Co Ltd | ロテプレドノール エタボネート水性懸濁液 |
JP2000007569A (ja) * | 1998-06-19 | 2000-01-11 | Senju Pharmaceut Co Ltd | 嗅覚障害治療剤 |
WO2002015878A1 (en) * | 2000-08-25 | 2002-02-28 | Senju Pharmaceutical Co., Ltd. | Aqueous suspension preparations |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011034192A1 (ja) * | 2009-09-17 | 2011-03-24 | 千寿製薬株式会社 | ラタノプロストを含有する水性点眼剤、並びにラタノプロストの樹脂への吸着の抑制方法 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2005053708A1 (ja) | 2007-06-28 |
JP4820648B2 (ja) | 2011-11-24 |
US20080306039A1 (en) | 2008-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2773142T3 (es) | Nuevo tratamiento | |
WO2009111057A4 (en) | Fulvestrant formulations | |
EP2170399A1 (en) | Intranasal administration of asenapine and pharmaceutical compositions therefor | |
EP1782816A1 (en) | Water-based medicinal composition containing azithromycin and method of preparing the same | |
JP2009533462A (ja) | ブリモニジンおよびチモロールの組成物 | |
JP2002537258A5 (ja) | ||
ES2527055T3 (es) | Formulaciones de compuestos 2-amino-1,3-propanodiol | |
WO2005053708A1 (ja) | ロテプレドノールエタボネート水性懸濁液剤 | |
TWI406663B (zh) | 含有氟甲松龍之懸浮型點眼劑 | |
JP2011057717A (ja) | イソプロピルウノプロストンの分解抑制方法 | |
AU612343B2 (en) | A dry formulation for the preparation of a suspension of diclofenac in salt form; and a stable suspension produced therefrom | |
FR2568773A1 (fr) | Nouvelles compositions pharmaceutiques administrables par voie nasale | |
HUE026162T2 (en) | Olopatadine preparation for topical nasal administration | |
JP2022101629A (ja) | 安定な医薬組成物 | |
JP2006509038A5 (ja) | ||
WO2004004682A2 (en) | Stable oily suspension of microgranules | |
JP6179204B2 (ja) | 粘膜用組成物及びその製造方法 | |
JP2006111621A (ja) | ピレノキシン懸濁型点眼剤 | |
WO1998030221A1 (fr) | Composition de type emulsion huile/eau a usage ophtalmique et contenant du difluprednate | |
TW201625219A (zh) | 液體組成物及其製造方法 | |
JPH10259132A (ja) | 点鼻用水性懸濁液 | |
JP6913792B2 (ja) | 局所粘膜適用水性組成物 | |
WO2024071349A1 (ja) | ヘテロシクリデンアセトアミド誘導体を含む配合剤 | |
EP0323762B1 (fr) | Nouvelles compositions anti-tussives et leur procédé d'obtention | |
KR20110119829A (ko) | 저용해도 물질 현탁액의 제조 방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005515924 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10581244 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |
Ref document number: 04819815 Country of ref document: EP Kind code of ref document: A1 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 4819815 Country of ref document: EP |